Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ambrosia Biosciences

Explore full profile

Small molecule therapies for obesity and metabolic disorders, delivered orally

Boulder, United StatesFounded 2020Biotech & Life Sciences
Valuation $250–500M Last recorded · 2026
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Ambrosia Biosciences and the history behind them.

About Ambrosia Biosciences

Ambrosia Biosciences Inc. is a drug discovery company focused on developing orally delivered, small molecule-based therapies aimed at treating obesity and other metabolic disorders. The company operates in the biotechnology sector, primarily targeting healthcare providers and patients dealing with metabolic health issues. Ambrosia Biosciences collaborates with seasoned biotech investors to leverage their expertise and drive forward its drug discovery programs. The business model revolves around the research, development, and eventual commercialization of these therapeutic solutions. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Boulder, United States
Employees
36
Open positions
1
Dealroom signal
73.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Weight Management, Metabolism, Biotech and Pharma, Small Molecules, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Mar 2026 $100M $400M Janus Henderson Investors · Blue Owl Capital · BVF Partners · Boulder Ventures ↗
SERIES AOther financing Dec 2024 $9M $80M Boulder Ventures · Merck & Co. · BVF Partners ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Ambrosia Biosciences website traffic

Latest recorded traffic for Ambrosia Biosciences is 2.4K monthly website visits, down 7.7% over the last three months. Ambrosia Biosciences's team grew 2.9% over the past year.

Latest monthly visits2.4K 3-month web change-7.7% 1-year team growth+2.9%
Monthly website visitsAug 2024–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
Scientist, Process ChemistryBoulder, CO · Other · Aug 11, 2026
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
MetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases New York City, United States Acquired 68 $505M $4.9B
ProLynxExtending medicine impact with ultra-long-acting therapies Brentwood, United States Operational
Zealand PharmaDiscovery, design and development of innovative peptide-based medicines Søborg, Denmark Operational
Verdiva BioOral therapies for obesity and cardiometabolic disorders London, United Kingdom Operational
Raziel TherapeuticsRaziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction Jerusalem, Israel Operational
Alveus TherapeuticsNext-generation obesity and metabolic disease therapies Philadelphia, United States Operational
Kailera TherapeuticsA clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions Waltham, United States Operational
Ambagon TherapeuticsBiotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment Eindhoven, Netherlands Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • BVF Partners
  • Boulder Ventures
  • Merck & Co.
  • Blue Owl Capital
  • Redmile Group
  • Deep Track Capital
  • Janus Henderson Investors
  • Samsara BioCapital

Talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ambrosia Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ambrosia Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.